Danirixin Chemical Properties

Melting point:

>153°C (dec.)

Boiling point:

533.1±50.0 °C(Predicted)

Density 

1.467±0.06 g/cm3(Predicted)

storage temp. 

Refrigerator

solubility 

Methanol (Slightly)

pka

4.95±0.10(Predicted)

form 

Solid

color 

White to Light Brown

Danirixin Usage And Synthesis

Uses

Antidiabetic (β3 adrenoreceptor agonist).

Biological Activity

Danirixin (GSK1325756) is an orally active, selective CXC chemokine receptor 2 (CXCR2) antagonist with 78-fold lower affinity toward CXCR1 (CXCR2/CXCR1 IC50 = 12.5/977 nM by competitive binding against 0.225 nM [125I] CXCL8). Danirixin blocks agonist-induced neutrophil CD11b expression in vitro (IC50 = 420/890 nM against induction by 10 nM human CXCL1/r at CXCL2 using rat/human whole blood) and prevents lung neutrophils influx in rats in vivo following aerosol lipopolysaccharide or ozone challenge (ED50 = 1.4 and 16 mg/kg, respectively).

Danirixin(954126-98-8)Related Product Information

• N-((S)-1-(4-((S)-2-(2,4-dichlorophenylsulfonaMido)-3-hydroxypropanoyl)piperazin-1-yl)-4-Methyl-1-oxopentan-2-yl)benzo[b]thiophene-2-carboxaMide
• GSK-2126458
• ABT 702 Dihydrochloride
• daprodustat,GSK1278863
• GSK1940029
• GSK 189254A
• GSK2110183
• gsk2200150a
• 4-(4-fluorophenyl)-N-(1H-indazol-5-yl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide
• 4-Methoxy-N-(2,4,6-triMethylphenyl)benzenesulfonaMide, 97%